九安医疗(002432) - 2015 Q1 - 季度财报

Revenue and Profitability - Revenue for Q1 2015 was CNY 107,181,295.34, representing a 4.02% increase compared to CNY 103,039,533.44 in the same period last year[8] - Net profit attributable to shareholders was CNY -16,867,877.16, a significant decrease of 4,991.11% from CNY 344,867.93 in the previous year[8] - Basic and diluted earnings per share were both CNY -0.0453, down 5,133.33% from CNY 0.0009 in the previous year[8] - The company expects a net loss for the first half of 2015, projecting a loss between -4,000,000 and -2,000,000, compared to a net profit of -760,680 in the same period last year[18] Cash Flow and Financial Position - Net cash flow from operating activities was CNY -36,397,102.41, which is a 114.54% decline compared to CNY -16,964,853.11 in the same period last year[8] - Cash and cash equivalents decreased by 43.56% to 66,541,394.80 due to negative operating cash flow and repayment of bank loans[15] - Net cash flow from operating activities was negative at -36,397,102.41, an increase of 114.54% in outflows compared to the previous period[15] Assets and Shareholder Information - Total assets at the end of the reporting period were CNY 986,790,691.35, a decrease of 1.56% from CNY 1,002,440,893.94 at the end of the previous year[8] - Net assets attributable to shareholders decreased by 3.03% to CNY 735,747,113.16 from CNY 758,752,957.24 at the end of the previous year[8] - The total number of ordinary shareholders at the end of the reporting period was 29,611[11] - The largest shareholder, Shihezi Sanhe Equity Investment Partnership, held 44.74% of shares, totaling 166,417,302 shares[11] - There were no significant changes in the company's shareholder structure or any repurchase transactions during the reporting period[12] Expenses and Investments - Research and development expenses rose by 31.52% to 32,336,847.60 as the company increased its investment in R&D[15] - Management expenses increased by 38.85% to 33,599,840.96 due to expansion in overseas markets and increased R&D investment[15] - Financial expenses decreased by 97.19% to -71,044.79 due to reduced interest from bank deposits invested in principal-protected financial products[15] Other Income and Gains - The company reported non-recurring gains and losses totaling CNY 2,628,662.03 after tax[9] - Other income surged by 3739.48% to 3,123,472.11, attributed to revenue from a collaboration project with Tianjin University[15] - Deferred income decreased by 100% as it was realized during the reporting period[15] Future Outlook - The company anticipates increased sales expenses and management costs due to overseas subsidiary activities and promotional efforts, contributing to the expected losses[18]